Fig. 1: Agreement between RCTs and their RWD emulations in FinnGen. | Nature Genetics

Fig. 1: Agreement between RCTs and their RWD emulations in FinnGen.

From: Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design

Fig. 1

a, Comparison of the estimates (HR and 95% CI) of the RCT and their emulation in FinnGen. Points represent estimated HRs; horizontal lines denote 95% CI. The vertical continuous line indicates the null value (HR = 1). Empareg, BI 10773 (Empagliflozin) cardiovascular outcome event trial in patients with T2D mellitus (nRCT = 7,020, nEmulation = 4,522); Tecos, sitagliptin cardiovascular outcomes study (MK-0431-082; nRCT = 14,514, nEmulation = 1,094); Aristotle, apixaban for the prevention of stroke in patients with AF (nRCT = 18,240, nEmulation = 2,292); Rocket, an efficacy and safety study of rivaroxaban with warfarin for the prevention of stroke and noncentral nervous system systemic embolism in patients with nonvalvular AF (nRCT = 13,916, nEmulation = 1,030). b, Kaplan–Meier plots for primary endpoints in FinnGen trial emulations. Lines represent the estimated survival (or event-free) probability over time. Shaded areas indicate 95% CI.

Source data

Back to article page